Clinical Trial Update: Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 randomized study comparing standard-of-care treatment to an immune-based combination for relapsed stage III non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Non-small-cell Lung Cancer Patients | Phase 2 | Status: RECRUITING